May 2018; 5 (3) ArticleOpen Access
Multicenter reliability of semiautomatic retinal layer segmentation using OCT
Timm Oberwahrenbrock, Ghislaine L. Traber, Sebastian Lukas, Iñigo Gabilondo, Rachel Nolan, Christopher Songster, Lisanne Balk, Axel Petzold, Friedemann Paul, Pablo Villoslada, Alexander U. Brandt, Ari J. Green, Sven Schippling
First published March 13, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000449
Timm Oberwahrenbrock
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Ghislaine L. Traber
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Sebastian Lukas
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Iñigo Gabilondo
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Rachel Nolan
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Christopher Songster
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Lisanne Balk
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Axel Petzold
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Friedemann Paul
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Pablo Villoslada
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Alexander U. Brandt
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Ari J. Green
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Sven Schippling
From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
Multicenter reliability of semiautomatic retinal layer segmentation using OCT
Timm Oberwahrenbrock, Ghislaine L. Traber, Sebastian Lukas, Iñigo Gabilondo, Rachel Nolan, Christopher Songster, Lisanne Balk, Axel Petzold, Friedemann Paul, Pablo Villoslada, Alexander U. Brandt, Ari J. Green, Sven Schippling
Neurol Neuroimmunol Neuroinflamm May 2018, 5 (3) e449; DOI: 10.1212/NXI.0000000000000449
Citation Manager Formats
Make Comment
See Comments
Downloads
1117
Article Information
vol. 5 no. 3 e449
PubMed:
Online ISSN:
History:
- Received October 3, 2017
- Accepted in final form January 23, 2018
- First Published March 13, 2018.
Copyright & Usage:
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Author Disclosures
- Timm Oberwahrenbrock, PhD*,
- Ghislaine L. Traber, MD*,
- Sebastian Lukas,
- Iñigo Gabilondo, MD,
- Rachel Nolan, BA,
- Christopher Songster,
- Lisanne Balk, PhD,
- Axel Petzold, MD,
- Friedemann Paul, MD,
- Pablo Villoslada, MD,
- Alexander U. Brandt, MD,
- Ari J. Green, MD** and
- Sven Schippling, MD**
- Timm Oberwahrenbrock, PhD*,
NONE
NONE
(1) TEVA GmbH Germany, speaker honoraria (2) Bayer Germany, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Federal Ministry of Education and Research (BMBF), EXISTS 03EFEB079, 2 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ghislaine L. Traber, MD*,
NONE
NONE
Santhera; travel honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sebastian Lukas,
NONE
NONE
Genzyme Bayer
NONE
NONE
NONE
(1) Heidelberg Engineering GmbH CH, Application and Service Engineer, 1.5
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Iñigo Gabilondo, MD,
NONE
NONE
NONE
Review Editor in Neuro-Ophthalmology, part of the journal(s) Frontiers in Neurology. Since 2nd May 2017.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Juan Rodes grant from Instituto de Salud Carlos III ?JR15/00008? (co- funded by European Regional Development Fund/ European Social Fund, ?Investing in your future?)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rachel Nolan, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christopher Songster,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lisanne Balk, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Researcher in OCTIMS study, 5%, 3 years
(1) research support from TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Axel Petzold, MD,
Advisory board on optical coherence tomography in MS (OCTiMS, CNF2333A2301), Novartis.
NONE
NONE
Neuro-ophthalmology
Listed as inventor on a patent on neurofilaments filed by the VUmc (P91964EP00 and P91964US00).
NONE
NONE
Optical Coherence Tomography Quality Control Reading for Passos study (NCT01705236), Novartis.
NONE
NONE
NONE
OCTiMS study (CNF2333A2301), Novartis.
NONE
NONE
The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD,
Novartis OCTIMS study steering committee MedImmune steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- Pablo Villoslada, MD,
Bionure
NONE
NONE
Neurology & Therapy, editorial board, 2014-2016 Curr There Op Neurol, editorial board 2014-2016 Mult Scl & Demyel Dis, editorial board 2015-- Systems Medicine 2017--
1. Methyltioadenosine for the treatment of MS 2. Agonistic neurotrophic compounds for the treatment of brain diseases 3. Gene signature pattern as a biomarker for MS 4. Algorithm for reconstructing white matter tracts from diffusion images
NONE
Genentech
NONE
NONE
NONE
NONE
unrestricted grants from Novartis
Instituto de Salud Carlos III, European Commission, National MS Society, NIH
NONE
Fundacion Maraton TV3, GAEM Foundation
NONE
NONE
NONE
Bionure Spire Bioventures Health Engineering Mint-Labs Roche
NONE
providing expert testimony for Synthon regarding patent issues with glatiramer acetate
- Alexander U. Brandt, MD,
NONE
NONE
NONE
NONE
(1) Pending patent Perceptive Visual Computing based Postural Control Analysis. (2) Pending patent Multiple Sclerosis Biomarker (3) Pending patent Perceptive Sleep Motion Analysis (4) Pending patent for fovea morphometry
NONE
NONE
(1) Motognosis
NONE
(1) Serves on the executive board of IMSVISUAL
NONE
(1) Novartis Pharma (2) Biogen Idec
(1) BMWi, ZIM KF2443803KJ, PI, two years (2) BMWi, ZIM KF2291305AK3, Co-I, one year (3) BMWI, EXIST-FT 03EFEBE079, PI, two years (4) BMBF, NEU2 N2-ADVISIMS, Co-I, three years
NONE
(1) The Guthy Jackson Charitable Foundation Stock/Stock Options, Medical Equipment & Materials: (1) Motognosis, 2014 (ongoing)
NONE
NONE
NONE
NONE
NONE
NONE
- Ari J. Green, MD** and
Medimmune End Point adjudication committee, Novartis Pharmaceuticals OCTIMS sterring committee, Inception 5 Biosciences Founder and Steering Committee, Bionure Scientfic Advisory Board
NONE
NONE
JAMA Neurology Associate Editor Neurology Editorial Board December 2010-2015
Remyelination molecules and pathways
NONE
NONE
Inception 5 Sciences
NONE
NONE
NONE
Novartis Pharma OCTIMs, Inception Sciences SRA
NINDS R01 NS088155-01 NIA 2R01AG038791-06A1
NONE
National MS Society Sherak Foundation Hilton Foundation
Inception 5
NONE
NONE
NONE
NONE
Mylan Pharmaceuticals v Teva Pharmaceuticals Expert Witness
- Sven Schippling, MD**
1.Bayer Healthcare 2.Biogen 3.Merck Serono 4.Novartis 5.Sanofi Genzyme 6.TEVA
NONE
1.Bayer Healthcare, travel compensation, speaker honoraria 2.Biogen, travel compensation, speaker honoraria 3.Merck Serono, travel compensation, speaker honoraria 4.Sanofi Genzyme, travel compensation, speaker honoraria 5.TEVA, travel compensation, speaker honoraria
Frontiers in Neurology, Associate Editor
Therapeutic vaccination in PML using VP1 and IL7.
NONE
NONE
NONE
NONE
NONE
NONE
1. Sanofi Genzyme 2. Novartis
1. University of Zurich, Clinical Research Priority Program, Co-Director, 3 years
NONE
1. Betty and David Koetser Foundation for Brain Research 2. Swiss Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
Scientific Advisory Boards:
- From the NeuroCure Clinical Research Center (T.O., F.P., A.U.B.), Charité—Universitätsmedizin Berlin, Germany; Department of Ophthalmology (G.L.T.), University Hospital Zurich, University of Zurich; Neuroimmunology and Multiple Sclerosis Research Section (S.L., S.S.), Department of Neurology, University Hospital Zurich, University of Zurich, Switzerland; Center of Neuroimmunology (I.G., P.V.), Institut d'Investigacions Biomediques August Pi Sunyer (IDIBAPS)—Hospital Clinic, Barcelona, Spain; Division of Neuroinflammation and Glial Biology (R.N., C.S., A.J.G.), Department of Neurology, University of California San Francisco; Neuro-ophthalmology Division (A.J.G.), Department of Ophthalmology, University of California, San Francisco; Multiple Sclerosis Center (L.B., A.P.), Departments of Neurology and Ophthalmology, Neuro-ophthalmology Expertise Centre, VUmc, Amsterdam and Moorfields Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery and UCL, United Kingdom; Clinical and Experimental Multiple Sclerosis Research Center (F.P.), Department of Neurology, Charité—Universitätsmedizin Berlin; Experimental and Clinical Research Center (F.P., A.U.B.), Charité—Universitätsmedizin Berlin and Max-Delbrück Center for Molecular Medicine, Germany; Department of Methods and Experimental Psychology (I.G.), Faculty of Psychology and Education, Universidad de Deusto, Bilbao, Spain.
- Correspondence
Dr. Schippling sven.schippling{at}usz.ch
Article usage
Cited By...
Letters: Rapid online correspondence
- RE: Multicenter reliability of semiautomatic retinal layer segmentation using OCT
- Jagannadha Avasarala, Neurologist and neuroimmunologist, Greenville Health System
Submitted April 23, 2018
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Longitudinal Changes in the Retinal Microstructures of Eyes With Chiasmal CompressionGa-In Lee, Ki Young Son, Kyung-Ah Park et al.Neurology, October 22, 2020 -
Article
Retinal and optic nerve changes in microcephalyAn optical coherence tomography studyEleni Papageorgiou, Anastasia Pilat, Frank Proudlock et al.Neurology, July 11, 2018 -
Drugs and Devices
The application of optical coherence tomography in neurologic diseasesRamiro S. Maldonado, Pradeep Mettu, Mays El-Dairi et al.Neurology: Clinical Practice, September 17, 2015 -
Article
Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson diseaseJeeyun Ahn, Jee-Young Lee, Tae Wan Kim et al.Neurology, August 15, 2018